The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
KTE-X19 CAR T cell therapy in relapsed or refractory mantle-cell lymphoma
Open accessAbstract
BACKGROUND: Patients with relapsed or refractory mantle-cell lymphoma who have disease progression during or after the receipt of Bruton's tyrosine kinase (BTK) inhibitor therapy have a poor prognosis. KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, may have benefit in patients with relapsed or refractory mantle-cell lymphoma. METHODS: CAR T cells per kilogram of body weight. The primary end point was the percentage of patients with an objective response (complete or partial response) as assessed by an independent radiologic review committee according to the Lugano classification. Per the protocol, the primary efficacy analysis was to be conducted after 60 patients had been treated and followed for 7 months. RESULTS: A total of 74 patients were enrolled. KTE-X19 was manufactured for 71 patients and administered to 68. The primary efficacy analysis showed that 93% (95% confidence interval [CI], 84 to 98) of the 60 patients in the primary efficacy analysis had an objective response; 67% (95% CI, 53 to 78) had a complete response. In an intention-to-treat analysis involving all 74 patients, 85% had an objective response; 59% had a complete response. At a median follow-up of 12.3 months (range, 7.0 to 32.3), 57% of the 60 patients in the primary efficacy analysis were in remission. At 12 months, the estimated progression-free survival and overall survival were 61% and 83%, respectively. Common adverse events of grade 3 or higher were cytopenias (in 94% of the patients) and infections (in 32%). Grade 3 or higher cytokine release syndrome and neurologic events occurred in 15% and 31% of patients, respectively; none were fatal. Two grade 5 infectious adverse events occurred. CONCLUSIONS: KTE-X19 induced durable remissions in a majority of patients with relapsed or refractory mantle-cell lymphoma. The therapy led to serious and life-threatening toxic effects that were consistent with those reported with other CAR T-cell therapies. (Funded by Kite, a Gilead company; ZUMA-2 ClinicalTrials.gov number, NCT02601313.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These CAR T-cells were able to elicit complete responses (CR) in 32-67% of lymphoma patients and showed better CR rates in patients with leukemia (16-19).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [18]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“First, most CAR T cell trials to date have used autologous peripheral blood and apheresis as the main cell sources for manufacturing (9-18,21,22).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Self-citationCheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Revised response criteria for malignant lymphoma.
Cheson, B. D., Pfistner, B., Juweid, M., Gascoyne, R., Specht, L., Horning, S., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,537
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112
Self-citationInterval Estimation for a Binomial Proportion
Brown, L. D., Cai, T., & Dasgupta, A. (2001) · Statistical Science · doi:10.1214/ss/1009213286 · Cited by 3,746
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
A note on quantifying follow-up in studies of failure time
SCHEMPER, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,592
Locke, F. L., Ghobadi, A., Jacobson, C. A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., Timmerman, J. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30864-7 · Cited by 2,286
Self-citationTargeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306220 · Cited by 1,685
Self-citation2016 US lymphoid malignancy statistics by World Health Organization subtypes
Teras, L. R., DeSantis, C. E., Cerhan, J. R., Morton, L. M., Jemal, A., & Flowers, C. R. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21357 · Cited by 1,125
Flagged first, then by citations
Cited by
Sorted by citations
Berdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00933-8 · Cited by 1,756
Long-term outcomes following CAR T cell therapy: what we know so far
Cappell, K. M., & Kochenderfer, J. N. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00754-1 · Cited by 1,503
Recent advances and discoveries in the mechanisms and functions of CAR T cells
Larson, R. C., & Maus, M. V. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00323-z · Cited by 852
Shah, B. D., Ghobadi, A., Oluwole, O. O., Logan, A. C., Boissel, N., Cassaday, R. D., Leguay, T., Bishop, M. R., Topp, M. S., Tzachanis, D., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01222-8 · Cited by 858
Self-citationNatural killer cells in antitumour adoptive cell immunotherapy
Laskowski, T. J., Biederstädt, A., & Rezvani, K. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00491-0 · Cited by 810
Jacobson, C. A., Chávez, J. C., Sehgal, A. R., William, B. M., Munoz, J. L., Salles, G. A., Munshi, P. N., Casulo, C., Maloney, D. G., de Vos, S., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00591-x · Cited by 704
Self-citationCAR immune cells: design principles, resistance and the next generation
Labanieh, L., & Mackall, C. L. (2023) · Nature · doi:10.1038/s41586-023-05707-3 · Cited by 695
CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
Pan, K., Farrukh, H., Chittepu, V. C. S. R., Xu, H., Pan, C.-X., & Zhu, Z. G. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02327-z · Cited by 685
Marín, D., Li, Y., Başar, R., Rafei, H., Daher, M., Dou, J., Mohanty, V., Dede, M., Nieto, Y. L., Uprety, N., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02785-8 · Cited by 567
Side-effect management of chimeric antigen receptor (CAR) T-cell therapy
Schubert, M., Schmitt, M. W., Wang, L., Ramos, C. A., Jordan, K., Müller‐Tidow, C., & Dreger, P. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.10.478 · Cited by 502
From bench to bedside: the history and progress of CAR T cell therapy
Mitra, A., Barua, A., Huang, L., Ganguly, S., Feng, Q. F., & He, B. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1188049 · Cited by 526
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
Mato, A. R., Shah, N. N., Jurczak, W. J., Cheah, C. Y., Pagel, J. M., Woyach, J. A., Fakhri, B., Eyre, T. A., Lamanna, N., Patel, M. R., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00224-5 · Cited by 486
Self-citationHayden, P. J., Roddie, C., Bader, P., Basak, G. W., Bonig, H. B., Bonini, C., Chabannon, C., Ciceri, F., Corbacioglu, S., Ellard, R., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.12.003 · Cited by 486
Self-citationCAR T-cell therapy in autoimmune diseases
Schett, G. A., Mackensen, A., & Mougiakakos, D. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01126-1 · Cited by 449
Thompson, J. A., Schneider, B. J., Brahmer, J. R., Achufusi, A., Armand, P. A., Berkenstock, M., Bhatia, S., Budde, L. E., Chokshi, S., Davies, M. J., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0020 · Cited by 445
Bachy, E., Gouill, S. L., Blasi, R. D., Sesques, P., Manson, G., Cartron, G., Beauvais, D., Roulin, L., Gros, F., Rubio, M., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01969-y · Cited by 406
Self-citationCAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
Zhang, X., Zhu, L., Zhang, H., Chen, S., & Xiao, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.927153 · Cited by 460
A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains
Cappell, K. M., & Kochenderfer, J. N. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00530-z · Cited by 414
Snowden, J. A., Sánchez‐Ortega, I., Corbacioglu, S., Basak, G. W., Chabannon, C., de la Cámara, R., Dolstra, H., Duarte, R. F., Glaß, B., Greco, R., et al. (2022) · Bone Marrow Transplantation · doi:10.1038/s41409-022-01691-w · Cited by 400
CAR T Cells and T-Cell Therapies for Cancer
Brudno, J. N., Maus, M. V., & Hinrichs, C. S. (2024) · JAMA · doi:10.1001/jama.2024.19462 · Cited by 412
Rejeski, K., Subklewe, M., Aljurf, M. D., Bachy, E., Balduzzi, A., Barba, P., Bruno, B., Benjamin, R., Carrabba, M. G., Chabannon, C., et al. (2023) · Blood · doi:10.1182/blood.2023020578 · Cited by 395
Self-citationCAR T cell killing requires the IFNγR pathway in solid but not liquid tumours
Larson, R. C., Kann, M. C., Bailey, S. R., Haradhvala, N. J., Llopis, P. D. L. M. M., Bouffard, A. A., Scarfò, I., Leick, M. B., Grauwet, K., Berger, T. R., et al. (2022) · Nature · doi:10.1038/s41586-022-04585-5 · Cited by 365
Tumor Immune Microenvironment during Epithelial–Mesenchymal Transition
Taki, M., Abiko, K., Ukita, M., Murakami, R., Yamanoi, K., Yamaguchi, K. D., Hamanishi, J., Baba, T., Matsumura, N., & Mandai, M. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4459 · Cited by 368
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
Smith, M., Dai, A., Ghilardi, G., Amelsberg, K. V., Devlin, S. M., Pajarillo, R., Slingerland, J. B., Beghi, S., Herrera, P. S., Giardina, P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01702-9 · Cited by 349
Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy
Chong, E. A., Ruella, M., & Schuster, S. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2030164 · Cited by 340
Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion
Amini, L., Silbert, S. K., Maude, S. L., Nastoupil, L. J., Ramos, C. A., Brentjens, R. J., Sauter, C. S., Shah, N. N., & Abou‐El‐Enein, M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00607-3 · Cited by 347
Wang, M. L., Munoz, J. L., Goy, A. H., Locke, F. L., Jacobson, C. A., Hill, B. T., Timmerman, J. M., Holmes, H. E., Jaglowski, S. M., Flinn, I. W., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02370 · Cited by 337
Self-citationCD8 T-cell subsets: heterogeneity, functions, and therapeutic potential
Koh, C., Lee, S., Kwak, M., Kim, B., & Chung, Y. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01105-x · Cited by 379
Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy
Abou-el-Enein, M., Elsallab, M., Feldman, S. A., Fesnak, A. D., Heslop, H. E., Marks, P., Till, B. G., Bauer, G., & Savoldo, B. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0084 · Cited by 321
Budde, L. E., Assouline, S., Sehn, L. H., Schuster, S. J., Yoon, S.-S., Yoon, D. H., Matasar, M. J., Bosch, F., Kim, W. S., Nastoupil, L. J., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00931 · Cited by 320
Self-citationCurrent understanding and management of CAR T cell-associated toxicities
Brudno, J. N., & Kochenderfer, J. N. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00903-0 · Cited by 352
Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy
Cappell, K. M., Sherry, R. M., Yang, J. C.-H., Goff, S. L., Vanasse, D., McIntyre, L. S., Rosenberg, S. A., & Kochenderfer, J. N. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01467 · Cited by 315
Xiao, X., Huang, S., Chen, S., Wang, Y., Sun, Q., Xu, X., & Li, Y. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02148-6 · Cited by 347
CAR-T cell manufacturing: Major process parameters and next-generation strategies
Ceja, M. A., Khericha, M., Harris, C. M., Puig-Saus, C., & Chen, Y. Y. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20230903 · Cited by 349
Nanomaterials for T-cell cancer immunotherapy
Gong, N., Sheppard, N. C., Billingsley, M. M., June, C. H., & Mitchell, M. J. (2021) · Nature Nanotechnology · doi:10.1038/s41565-020-00822-y · Cited by 316
Cohen, A. D., Parekh, S., Santomasso, B. D., Gállego Pérez-Larraya, J., van de Donk, N. W. C. J., Arnulf, B., Mateos, M.-V., Lendvai, N., Jackson, C. C., De Braganca, K. C., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00629-1 · Cited by 308
Neelapu, S. S., Dickinson, M. J., Munoz, J. L., Ulrickson, M. L., Thiéblemont, C., Oluwole, O. O., Herrera, A. F., Ujjani, C. S., Lin, Y., Riedell, P. A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01731-4 · Cited by 306
Self-citationdos Santos, D. M. C., Tix, T., Shouval, R., Gafter-Gvili, A., Alberge, J.-B., Cliff, E. R. S., Theurich, S., von Bergwelt-Baildon, M., Ghobrial, I., Subklewe, M., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03084-6 · Cited by 266
Non-viral precision T cell receptor replacement for personalized cell therapy
Foy, S. P., Jacoby, K., Bota, D. A., Hunter, T., Pan, Z., Stawiski, E. W., Ma, Y., Lu, W., Peng, S., Wang, C. L., et al. (2022) · Nature · doi:10.1038/s41586-022-05531-1 · Cited by 301
Self-citationMaus, M. V., Alexander, S., Bishop, M. R., Brudno, J. N., Callahan, C. A., Davila, M. L., Diamonte, C., Dietrich, J., Fitzgerald, J. C., Frigault, M. J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001511 · Cited by 287
Self-citationChallenges and new technologies in adoptive cell therapy
Zhang, P., Zhang, G., & Wan, X. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01492-8 · Cited by 291
Arcangeli, S., Bove, C., Mezzanotte, C., Camisa, B., Falcone, L., Manfredi, F., Bezzecchi, E., Khoury, R. E., Norata, R., Sanvito, F., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci150807 · Cited by 259
Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany
Albinger, N., Hartmann, J., & Ullrich, E. (2021) · Gene Therapy · doi:10.1038/s41434-021-00246-w · Cited by 236
Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL
Sheth, V., & Gauthier, J. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-01134-4 · Cited by 244
Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity
Ma, L., Hostetler, A., Morgan, D. M., Maiorino, L., Sulkaj, I., Whittaker, C. A., Neeser, A., Pires, I. S., Yousefpour, P., Gregory, J. R., et al. (2023) · Cell · doi:10.1016/j.cell.2023.06.002 · Cited by 232
The journey of CAR-T therapy in hematological malignancies
Lu, J., & Jiang, G. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01663-0 · Cited by 240
Enhanced safety and efficacy of protease-regulated CAR-T cell receptors
Labanieh, L., Majzner, R. G., Klysz, D. D., Sotillo, E., Fisher, C., Vilches-Moure, J. G., Pacheco, K. Z., Malipatlolla, M. B., Xu, P., Hui, J. H., et al. (2022) · Cell · doi:10.1016/j.cell.2022.03.041 · Cited by 232
Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities
Falchi, L., Vardhana, S. A., & Salles, G. A. (2022) · Blood · doi:10.1182/blood.2021011994 · Cited by 222
Dagar, G., Gupta, A., Masoodi, T., Nisar, S., Merhi, M., Hashem, S., Chauhan, R., Dagar, M., Mirza, S., Bagga, P., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04292-3 · Cited by 229
CAR-T Cell Therapy: the Efficacy and Toxicity Balance
Chohan, K. L., Siegler, E. L., & Kenderian, S. S. (2023) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-023-00687-7 · Cited by 227
Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead
Kirtane, K., Elmariah, H., Chung, C. H., & Abate‐Daga, D. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002723 · Cited by 205
Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy
Chong, E. A., Alanio, C., Svoboda, J., Nasta, S. D., Landsburg, D. J., Lacey, S. F., Ruella, M., Bhattacharyya, S., Wherry, E. J., & Schuster, S. J. (2021) · Blood · doi:10.1182/blood.2021012634 · Cited by 209
Shah, B. D., Bishop, M. R., Oluwole, O. O., Logan, A. C., Baer, M. R., Donnellan, W. B., O’Dwyer, K. M., Holmes, H. E., Arellano, M. L., Ghobadi, A., et al. (2021) · Blood · doi:10.1182/blood.2020009098 · Cited by 209
Self-citationGamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future
Saura‐Esteller, J., de Jong, M., King, L. A., Ensing, E., Winograd, B., de Gruijl, T. D., Parren, P. W. H. I., & van der Vliet, H. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.915837 · Cited by 210
Wang, Y., Jain, P., Locke, F. L., Maurer, M. J., Frank, M. J., Munoz, J. L., Dahiya, S., Beitinjaneh, A., Jacobs, M. T., McGuirk, J. P., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01797 · Cited by 195
Self-citationCurrent updates on generations, approvals, and clinical trials of CAR T-cell therapy
Dejenie, T. A., Medhin, M. T. G., Terefe, G. D., Admasu, F. T., Tesega, W. W., & Abebe, E. C. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2114254 · Cited by 210
Successes and challenges in clinical gene therapy
Kohn, D. B., Chen, Y. Y., & Spencer, M. J. (2023) · Gene Therapy · doi:10.1038/s41434-023-00390-5 · Cited by 209
From concept to cure: The evolution of CAR-T cell therapy
Patel, K. K., Tariveranmoshabad, M., Kadu, S., Shobaki, N., & June, C. H. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.005 · Cited by 211
Kok, N., Panella, D., Georgoudaki, A., Liu, H., Özkazanç, D., Kučerová, L., Duru, A. D., Spanholtz, J., & Raimo, M. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01382-5 · Cited by 191
Park, J. H., Nath, K., Devlin, S. M., Sauter, C. S., Palomba, M. L., Shah, G. L., Dahi, P. B., Lin, R. J., Scordo, M., Perales, M., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02404-6 · Cited by 196
Lickefett, B., Chu, L., Ortiz‐Maldonado, V., Warmuth, L., Barba, P., Doglio, M., Henderson, D. A., Hudecek, M., Kremer, A., Markman, J. L., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1303935 · Cited by 200
Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies
Ruella, M., Korell, F., Porazzi, P., & Maus, M. V. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00807-1 · Cited by 197
Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases
Cui, X., & Snapper, C. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.734471 · Cited by 179
Drug delivery systems for CRISPR-based genome editors
Madigan, V. J., Zhang, F., & Dahlman, J. E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00762-x · Cited by 193
Inosine induces stemness features in CAR-T cells and enhances potency
Klysz, D. D., Fowler, C., Malipatlolla, M. B., Stuani, L., Freitas, K. A., Chen, Y., Meier, S. L., Dániel, B., Sándor, K., Xu, P., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.01.002 · Cited by 181
Immunotherapy in hematologic malignancies: achievements, challenges and future prospects
Tang, L., Huang, Z., Mei, H., & Hu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01521-5 · Cited by 181
Wang, L. L., Janes, M. E., Kumbhojkar, N., Kapate, N., Clegg, J. R., Prakash, S., Heavey, M. K., Zhao, Z., Anselmo, A. C., & Mitragotri, S. (2021) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10214 · Cited by 162
Alu, A., Lei, H., Han, X., Wei, Y., & Wei, X. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01353-w · Cited by 159
Gazeau, N., Liang, E. C., Wu, Q. V., Voutsinas, J. M., Barba, P., Iacoboni, G., Kwon, M., Ortega, J. L. R., López‐Corral, L., Hernani, R., et al. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.04.001 · Cited by 185
T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome
Klebanoff, C. A., Chandran, S. S., Baker, B. M., Quezada, S. A., & Ribas, A. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00809-z · Cited by 164
Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy
Goldman, A., Maor, E., Bomze, D., Liu, J. E., Herrmann, J., Fein, J. A., Steingart, R. M., Mahmood, S., Schaffer, W. L., Perales, M., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.08.044 · Cited by 159
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021
Zelenetz, A. D., Gordon, L. I., Chang, J. E., Christian, B. A., Abramson, J. S., Advani, R. H., Bartlett, N. L., Budde, L. E., Caimi, P. F., de Vos, S., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0054 · Cited by 156
Dreyling, M. H., Doorduijn, J. K., Giné, E., Jerkeman, M., Walewski, J. A., Hutchings, M., Mey, U., Riise, J., Trněný, M., Vergote, V., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00184-3 · Cited by 164
Next generations of CAR-T cells - new therapeutic opportunities in hematology?
Tomasik, J., Jasiński, M., & Basak, G. W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1034707 · Cited by 166
Jain, P., & Wang, M. L. (2022) · American Journal of Hematology · doi:10.1002/ajh.26523 · Cited by 156
Self-citationChimeric antigen receptor T cell therapy for autoimmune disease
Chung, J. B., Brudno, J. N., Borie, D. C., & Kochenderfer, J. N. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01035-3 · Cited by 159
Juluri, K. R., Wu, Q. V., Voutsinas, J. M., Hou, J., Hirayama, A. V. V., Mullane, E., Miles, N., Maloney, D. G., Turtle, C. J., Bar, M., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020004142 · Cited by 159
Grant, S. J., Grimshaw, A. A., Silberstein, J., Murdaugh, D. L., Wildes, T. M., Rosko, A. E., & Giri, S. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.03.006 · Cited by 158
Metabolic challenges and interventions in CAR T cell therapy
Peng, J.-J., Wang, L., Li, Z., Ku, C., & Ho, P. (2023) · Science Immunology · doi:10.1126/sciimmunol.abq3016 · Cited by 156
T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors
Tsimberidou, A. M., Morris, K. V., Vo, H. H., Eck, S., Lin, Y., Rivas, J. M., & Andersson, B. S. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01115-0 · Cited by 155
Alnefaie, A., Albogami, S. M., Asiri, Y. A., Ahmad, T., Alotaibi, S. S., Al-Sanea, M. M., & Althobaiti, H. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.797440 · Cited by 163
Value and affordability of CAR T-cell therapy in the United States
Fiorenza, S., Ritchie, D. S., Ramsey, S. D., Turtle, C. J., & Roth, J. A. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-0956-8 · Cited by 152
Socioeconomic and Racial Disparity in Chimeric Antigen Receptor T Cell Therapy Access
Ahmed, N., Shahzad, M., Shippey, E., Bansal, R., Mushtaq, M. U., Mahmoudjafari, Z., Faisal, M. S., Hoffmann, M. S., Abdallah, A.-O. A., Divine, C. L., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.04.008 · Cited by 146
The use of RNA-based treatments in the field of cancer immunotherapy
Chehelgerdi, M., & Chehelgerdi, M. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01807-w · Cited by 149
Engineering-enhanced CAR T cells for improved cancer therapy
Milone, M. C., Xu, J., Chen, S., Collins, M. A., Zhou, J., Powell, D. J., & Melenhorst, J. J. (2021) · Nature Cancer · doi:10.1038/s43018-021-00241-5 · Cited by 148
Armitage, J. O., & Longo, D. L. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2202672 · Cited by 142
Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas
Sworder, B. J., Kurtz, D. M., Alig, S., Frank, M. J., Shukla, N., Garofalo, A., Macaulay, C. W., Esfahani, M. S., Olsen, M. N., Hamilton, J., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.12.005 · Cited by 147
Self-citationCo-Stimulatory Receptor Signaling in CAR-T Cells
Honikel, M. M., & Olejniczak, S. H. (2022) · Biomolecules · doi:10.3390/biom12091303 · Cited by 149
Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia
Leick, M. B., Silva, H. J., Scarfò, I., Larson, R. C., Choi, B. D., Bouffard, A. A., Gallagher, K., Schmidts, A., Bailey, S. R., Kann, M. C., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.04.001 · Cited by 138
Targeting immune checkpoints in hematological malignancies
Salik, B., Smyth, M. J., & Nakamura, K. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00947-6 · Cited by 113
A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies
Razeghian, E., Nasution, M. K. M., Rahman, H. S., Gardanova, Z. R., Abdelbasset, W. K., Surendar, A., Bokov, D. O., Suksatan, W., Nakhaei, P., Shariatzadeh, S., et al. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02510-7 · Cited by 147
Wehrli, M., Gallagher, K., Chen, Y., Leick, M. B., McAfee, S. L., El-Jawahri, A. R., DeFilipp, Z. M., Horick, N., O’Donnell, P. V., Spitzer, T. R., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003847 · Cited by 142
Wudhikarn, K., & Perales, M. (2022) · Bone Marrow Transplantation · doi:10.1038/s41409-022-01756-w · Cited by 151
Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities
Liu, Y., Zhou, X., & Wang, X. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01134-x · Cited by 142
Immunotherapy for nasopharyngeal carcinoma: Current status and prospects (Review)
Huang, H., Yao, Y., Deng, X., Huang, Z., Chen, Y., Wang, Z., Hong, H., Huang, H., & Lin, T. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5545 · Cited by 141
Allogeneic CAR Cell Therapy—More Than a Pipe Dream
Caldwell, K. J., Gottschalk, S. M., & Talleur, A. C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.618427 · Cited by 141
Gouill, S. L., Morschhauser, F., Chiron, D., Bouabdallah, K. K., Cartron, G., Casasnovas, O., Bodet‐Milin, C., Ragot, S., Bossard, C., Nadal, N., et al. (2020) · Blood · doi:10.1182/blood.2020008727 · Cited by 130
Overview of approved CAR‐T therapies, ongoing clinical trials, and its impact on clinical practice
Sengsayadeth, S. M., Savani, B. N., Oluwole, O. O., & Dholaria, B. (2021) · eJHaem · doi:10.1002/jha2.338 · Cited by 130
Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer
Saux, O. L., Ray-Coquard, I. L., & Labidi‐Galy, S. I. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.08.017 · Cited by 127
CAR‐NK cells: the next wave of cellular therapy for cancer
Daher, M., Garcia, L. M., Li, Y., & Rezvani, K. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1274 · Cited by 133
Metadata
- Authors
- Wang, M., Munoz, J., Goy, A., Locke, F. L., Jacobson, C. A., Hill, B. T., Timmerman, J. M., Holmes, H., Jaglowski, S., Flinn, I. W., McSweeney, P. A., Miklos, D. B., Pagel, J. M., Kersten, M.-J., Milpied, N., Fung, H., Topp, M. S., Houot, R., Beitinjaneh, A., Peng, W., Zheng, L., Rossi, J. M., Jain, R. K., Rao, A. V., & Reagan, P. M.
- Affiliations
- Cleveland Clinic (US)
- From the University of Texas M.D. Anderson Cancer Center, Houston (M.W.), and Texas Oncology, Dallas (H.H.); Banner M.D. Anderson Cancer Center, Gilbert, AZ (J.M.); John Theurer Cancer Center, Hackensack, NJ (A.G.); Moffitt Cancer Center, Tampa (F.L.L.), and the University of Miami, Miami (A.B.) — both in Florida; Dana–Farber Cancer Institute, Boston (C.A.J.); Cleveland Clinic Foundation, Cleveland (B.T.H.), and the Ohio State University Comprehensive Cancer Center, Columbus (S.J.); David Geffen...
- Fox Chase Cancer Center (US)
- Corresponding author
- Wang, Michael
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-04-02
- Volume
- 382
- Issue
- 14
- Pages
- 1331-1342
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7731441
- OpenAlex
- W3014583893
- Cited by
- 1,862
- References
- 30
- Citations by year
- 2026: 203 · 2025: 249 · 2024: 314 · 2023: 321 · 2022: 366 · 2021: 321 · 2020: 81
- FWCI
- 98.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Funders
- Kite, a Gilead Company
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- tisagenlecleucel, CD19 CAR T-cell therapy, BTK inhibitor resistance, objective response, complete response, progression-free survival, overall survival, cytokine release syndrome, neurological adverse events, cytopenia
- MeSH terms
- Receptors, Chimeric Antigen, Adult, Aged, Antineoplastic Agents, Combined Modality Therapy, Humans, Infusions, Intravenous, Leukapheresis, Middle Aged, Recurrence, T-Lymphocytes, Vidarabine, Survival Analysis, Immunotherapy, Adoptive, Antigens, CD19, Lymphoma, Mantle-Cell
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
